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Large and rare copy number variants (CNVs) at several loci have been shown to increase risk for schizophrenia.
Aiming to discover novel susceptibility CNV loci, we analyzed 6882 cases and 11 255 controls genotyped on
Illumina arrays, most of which have not been used for this purpose before. We identified genes enriched for
rare exonic CNVs among cases, and then attempted to replicate the findings in additional 14 568 cases and 15
274 controls. In a combined analysis of all samples, 12 distinct loci were enriched among cases with nominal
levels of significance (P < 0.05); however, none would survive correction for multiple testing. These loci include
recurrent deletions at 16p12.1, a locus previously associated with neurodevelopmental disorders (P 5 0.0084 in
the discovery sample andP 5 0.023 in the replication sample). Other plausible candidates include non-recurrent
deletions at the glutamate transporter gene SLC1A1, a CNV locus recently suggested to be involved in schizo-
phrenia through linkage analysis, and duplications at 1p36.33 andCGNL1. A burden analysis of large (>500 kb),
rare CNVs showed a 1.2% excess in cases after excluding known schizophrenia-associated loci, suggesting that
additional susceptibility loci exist. However, even larger samples are required for their discovery.
†Wellcome Trust Case Control Consortium 2, affiliations are provided in the Supplementary Material.
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INTRODUCTION
Copy number variants (CNVs) at several loci are now robustly
associated with schizophrenia (1–7). The majority of these are
flanked by low copy repeats (LCRs) which mediate their forma-
tion through non-allelic homologous recombination (NAHR).
Therefore, these CNVs occupy the same genomic locations
(i.e. they are recurrent). In addition to these recurrent CNVs,
two genes, NRXN1 and VIPR2, have also been associated with
schizophrenia when disrupted by non-recurrent CNVs with dif-
ferent breakpoints (8–10). All strongly implicated CNV loci in
schizophrenia are rare, CNVs at each locus being found in
0.082–0.59% of cases and even less often in controls (5,6).
Due to their rarity, very large sample sizes have been required
to identify these loci. For example, the latest CNV locus asso-
ciated with schizophrenia, a duplication of the Williams–
Beuren region, was identified with a sample of over 14 000
cases and 28 000 controls (11). It is logical that further suscepti-
bility loci exist, but have so far escaped identification due to their
rarity or lower penetrance.
Most strongly associated schizophrenia CNVs are implicated
in other neuropsychiatric disorders, such as autism spectrum dis-
order (ASD), attention deficit hyperactivity disorder, intellectual
disability (ID) and developmental delay (DD) (12–14). There
are also many further CNVs that increase susceptibility for ID/
DD/ASD (14) that have not been associated with schizophrenia.
This could also be due to power limitations: current CNV studies
in ID/DD have been much larger than in schizophrenia (5,14) and
the rate of these CNVs in schizophrenia is usually lower than in
ID/DD (15), making their discovery even harder. Therefore, it is
possible that some additional CNVs that are enriched in ID/DD
will also increase risk for schizophrenia, if tested in much larger
samples.
We reasoned that the best way to discover novel schizophrenia
susceptibility loci is by using new, very large schizophrenia
samples. We first examined rare CNVs in a discovery sample
of 6882 cases and 11 255 controls. These cases and most of the
controls have not been used before for the discovery of new
loci, except the WTCCC2 subset of the control sample which
figures in several papers and most meta-analyses. Loci that
showed evidence for association were followed up in the add-
itional 14 568 cases and 15 274 controls, bringing the total
number of samples analyzed to 48 000.
RESULTS
Novel candidate CNV loci
Each gene in the genomewas examined for exon-disrupting CNVs
in cases and controls. After excluding genes within previously
implicated loci (13 loci flanked by LCRs, and two individual
genes, NRXN1 and VIPR2, listed in Supplementary Material,
TableS3),genes in37regions (containing72genes)wereenriched
among our discovery cases with nominal levels of significance
(two-sided Fisher’s exact P, 0.05, Supplementary Material,
TablesS5andS6).Weremovedfour regions fromsubsequentana-
lyses after manual inspection of their Z-scores, Log R ratio and
B-allele frequency traces found them to be unreliable. The signifi-
cance for none of the genes would survive a conservative Bonfer-
roni correction for multiple testing of 20 000 genes separately for
deletions and duplications (P, 1.25 × 1026). Restricting the
analysis to only individuals of European ancestry (90% of
the sample) did not change these results (data not presented). In
the replication data, CNVs of the same type (deletions or duplica-
tions) at 20 of the 33 loci were more common among cases (Sup-
plementary Material, Table S5) but only one (16p12.1) was
nominally significant (without multiple-testing correction). In a
combined analysis of the discovery and replication samples,
genes in 12 distinct regions remained significant (Cochran–
Mantel–Haenszel (CMH) P, 0.05, Table 1). Again, the signifi-
cance for none of these genes would survive genome-wide correc-
tion for multiple testing.
We find the best evidence for the following loci (details in the
Supplementary Material):
Deletions at 16p12.1 are the most likely finding as it is the only
locus significant in the replication dataset on its own and is a
known pathogenic locus associated with ID/DD/ASD (14,16).
It includes seven genes disrupted by recurrent deletions
flanked by LCRs (Supplementary Material, Fig. S13). In our dis-
covery sample, the deletion was found in 13 cases and 6 controls
(0.19 versus 0.053%, two-sided Fisher’s exact P ¼ 0.0084). In
our replication sample, the deletion was found in a further 20
cases and 9 controls (0.14 versus 0.059%, one-sided Fisher’s
exact P ¼ 0.023). A combined analysis of all data found the de-
letion in 0.15% of cases and 0.057% of controls, CMH P ¼
0.0016, odds ratio (OR) ¼ 2.72, 95% confidence interval
(95%CI) ¼ 1.48–5.02 (Table 1).
Our most significant finding involves non-recurrent duplica-
tions of five genes at 1p36.33 (GNB1, CALML6, TMEM52,
KIAA1751, GABRD), which partially overlap another known
pathogenic locus when deleted: 1p36 (17,18). In the combined
data, duplications are found in 0.065% of cases and 0.0075%
of controls, CMH P ¼ 0.00050, OR ¼ 8.66, 95%CI ¼ 1.97–
38.12 (Table 1). As these non-recurrent CNVs have different
breakpoints, the five genes have slightly different CNV counts
(Supplementary Material, Fig. S3 and Table S5).
The strongest single gene region is CGNL1 (chr15:57.67–
57.84 Mb). In the combined data, CGNL1 duplications are found
in 0.32% of cases and 0.19% of controls, CMH P ¼ 0.0019,
OR ¼ 1.71, 95%CI¼ 1.19–2.46 (Table 1 and Supplementary
Material, Fig. S12).
Another good single gene candidate is the glutamate trans-
porter SLC1A1, where analysis of all data found deletions in
0.047% of cases and 0.0075% of controls, CMH P ¼ 0.0098,
OR ¼ 6.19, 95%CI ¼ 1.36–28.24 (Table 1 and Supplementary
Material, Fig. S11).
Burden analysis
An increased burden of large, rare CNVs is well established in
schizophrenia (2,7). To determine how much of this excess is
explained by already implicated loci, we performed a CNV
burden analysis in our discovery sample with and without the in-
clusion of loci implicated in the current study (regions in Table 1)
and 15 loci from previous studies (Supplementary Material,
Table S3). There is a 2.5% excess of all CNVs .500 kb in
cases, of which 1.3% is accounted for by already implicated
loci (Fig. 1 and Supplementary Material, Table S3). The remain-
ing 1.2% excess in cases comes mostly from deletions .1 Mb,
and from duplications .500 kb (details in Supplementary
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Table 1. Novel candidate CNV loci
Locus/gene Location (Mb) Type Discovery
(case/control)
Replication
(case/control)
Discovery P
(two-sided
Fisher)
Replication P
(one-sided
Fisher)
Combined P
(CMH)
Totals %
case/control
Odds ratio (95%CI)
1p36.33 (GNB1, CALML6,
TMEM52, KIAA1751, GABRD)
chr1:1.85–2.11 Dup 9/0 (0.13%/0%) 5/2 (0.034%/0.013%) 0.00016 0.21 0.0005 0.065%/0.0075% 8.66 (1.97–38.12)
AQP12A, KIF1A chr2:241.63–241.75 Dup 51/39 (0.74%/0.35%) 23/25 (0.16%/0.16%) 0.00042 0.61 0.0028 0.34%/0.24% 1.43 (1.02–2.00)
ELOVL6 chr4:110.97–111.12 Dup 4/0 (0.058%/0%) 3/1 (0.021%/0.0065%) 0.021 0.29 0.024 0.033%/0.0038% 8.66 (1.07–70.39)
FAM149A, FLJ38576,
CYP4V2
chr4:187.05–187.14 Dup 9/0 (0.13%/0%) 1/3 (0.0069%/0.02%) 0.00016 0.93 0.02 0.047%/0.011% 4.12 (1.13–14.99)
TRIML1, TRIML2 chr4:189.01–189.07 Del 8/3 (0.12%/0.027%) 4/2 (0.027%/0.013%) 0.026 0.32 0.024 0.056%/0.019% 2.97 (1.05–8.43)
IRGM, ZNF300, SMIM3 chr5:150.16–150.30 Del 4/0 (0.058%/0%) 5/1 (0.034%/0.0065%) 0.021 0.099 0.015 0.042%/0.0038% 11.14 (1.41–87.90)
PHACTR2 chr6:144–144.15 Dup 5/1 (0.073%/0.0089%) 5/2 (0.034%/0.013%) 0.032 0.21 0.03 0.047%/0.011% 4.12 (1.13–14.99)
GLIS3 chr9:3.82–4.3 Del 5/0 (0.073%/0%) 2/0 (0.014%/0%) 0.0079 0.24 0.0084 0.033%/0% NA (1.06–324.96)
SLC1A1 chr9:4.49–4.59 Del 6/1 (0.087%/0.0089%) 4/1 (0.027%/0.0065%) 0.014 0.17 0.0098 0.047%/0.0075% 6.19 (1.36–28.24)
CGNL1 chr15:57.67–57.84 Dup 35/25 (0.51%/0.22%) 34/25 (0.23%/0.16%) 0.0019 0.11 0.0019 0.32%/0.19% 1.71 (1.19–2.46)
16p12.1 (7 genes) chr16:21.95–22.43 Del 13/6 (0.19%/0.053%) 20/9 (0.14%/0.059%) 0.0084 0.023 0.0016 0.15%/0.057% 2.72 (1.48–5.02)
GALR1 chr18:74.96–74.98 Dup 5/0 (0.073%/0%) 0/0 (0%/0%) 0.0079 1 0.016 0.023%/0% NA (0.75–246.1)
Discovery ¼ 6882 cases and 11 255 controls. Replication ¼ 14 568 cases and 15 274 controls. CMH ¼ Cochran–Mantel–Haenszel test. Type: Dup ¼ duplications and Del ¼ deletion. CI ¼ confidence interval.
Fisher ¼ Fisher’s exact test. The columns for discovery and replication datasets display the numbers of CNVs that intersect exons in the gene (or the gene with the strongestP-value in regions that contain multiple
genes) and the % of cases and controls affected by these CNVs.
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analysis before and after removing schizophrenia-associated
CNVs. We found that of the 2.5% excess of all CNVs .500 kb
in cases, 1.3% comes from loci implicated in the current (0.2%)
and previously published studies (1.1%). As our discovery
sample has 80% power to detect around half of the previously
implicated CNVs (Fig. 2), we speculate that the remaining 1.2%
excess yet to be discovered for CNVs.500 kb will be attributed
to CNVs with lower population frequencies and/or smaller ORs
than those already identified. These will therefore require even
larger samples for their discovery, but some are likely to be just
singleton observations, where association analysis will fail. We
feel that burden analysis of CNVs smaller than 500 kb, even on
the high-quality arrays we used, is still subjected to too many po-
tential biases to be reliable (unlike selected individual loci, that
can be inspected further, see Materials and Methods and
Results), and we are unable to speculate about the precise
excess of smaller CNVs. We expect such loci should also exist,
but might also have lower ORs and/or frequencies.
Schizophrenia has a high heritability (81% according to the
largest review of twin studies) (20). CNVs probably contribute
to this heritability; however, they can explain only a small
part of it. Our results suggest that only 2.5% of patients (versus
1% of controls) carry a confirmed schizophrenia-associated
CNV (Supplementary Material, Table S3), with an additional
1.2% excess burden of large CNVs (Fig. 1). Not all of these
would contribute to heritability, as some 16% of the .500 kb
CNVs occur de novo (21) as do 9–80% of those at specific
schizophrenia-associated loci (15,22). In addition, their
penetrance is not complete (15), which would lower theircontribu-
tion to heritability. We cannot speculate on the extent of the con-
tribution of smaller CNVs, but no doubt they contribute as well.
Deletions at 16p12.1
Although we found no novel genome-wide significant associa-
tions, we report deletions at 16p12.1 as the most likely new
risk locus. This deletion has previously been observed in a
schizophrenia cohort (16), but that study lacked the statistical
power to implicate it. Here we show for the first time enrichments
with nominal levels of significance in both our discovery and
replication cases, resulting in a combined P-value of 1.6 ×
1023. The deletion has the hallmarks of almost all robustly asso-
ciated CNVs, in that it is recurrent, is flanked by LCRs, disrupts
multiple genes and is a susceptibility locus for developmental
disorders (15,16). The clinical features previously associated
with 16p12.1 deletions include DD, speech delay, epilepsy and
craniofacial and skeletal abnormalities (16). 16p12.1 deletions
are found in 0.2% of ID/DD patients (16) and we observe them
in 0.15% of schizophrenia cases and 0.057% of controls. The
combination of a modest OR (OR ¼ 2.72) for developing
schizophrenia and a low frequency could explain why it has
not been identified until now (our discovery sample has ,80%
power to detect its association at a 0.05; Fig. 2).
Around a quarter of ID/DD patients with a 16p12.1 deletion
also carry an additional pathogenic CNV (defined as a CNV asso-
ciated with ID/DD or .500 kb) (15,16) and in those that do so,
the phenotype is more severe (16). In our discovery sample we
found only 1 of 13 cases to also carry an additional pathogenic
CNV (a 15q11.2 deletion) and none out of the six controls. Al-
though this lower rate is not statistically significant compared
with the ID/DD data, it is plausible that individuals with a
second hit are more likely to have ID/DD, while those with
only the 16p12.1 deletion are more at risk of developing schizo-
phrenia (23). A structural polymorphism with two configura-
tions is known to affect the orientation of LCRs that mediate
the formation of 16p12.1 deletions (23,24). Individuals with
the more common configuration have LCRs in direct orientation
(23,24), which is a mechanistic requirement for NAHR to form
deletions. As this risk configuration is found at different frequen-
cies across European (83%), African (98%) and Asian popula-
tions (72%), there is a potential for population stratification to
bias 16p12.1 associations (23,24). However, when we restrict
our analysis to individuals of European decent, the deletion
shows even greater enrichment (13/6307 cases, 5/10 676 con-
trols, two-sided Fisher’s exact P ¼ 0.0029).
1p36.33 duplications
The five genes disrupted by duplications in 0.065% of cases and
0.0075% of controls (CMH P ¼ 0.0005) are located within
1.8 Mb of the 10 Mb 1p36 deletion syndrome region, a known
pathogenic locus for ID/DD when deleted (17,18). The gene with
the strongest P-value in this region is KIAA1751 (P¼ 0.0005),
but it is uncharacterized. A more likely candidate is the gamma-
aminobutyric acid (GABA) A receptor, delta (GABRD) (Supple-
mentary Material, Fig. S3 and Table S5) which has been suggested
to be responsible for the neuropsychiatric characteristics seen in
1p36 deletion patients as it is highly expressed in brain and
Figure 2. Discovery sample power calculation. The curve represents the point
above which our discovery sample had 80% power to detect associations at
alpha 0.05. Thex-axis indicates the frequency of the CNV in controls, ona logarith-
mic scale (e.g.24.0 equates to a rate of one CNV per 10 000 people). The y-axis is
the OR for increasing risk to develop schizophrenia. For reference we indicate the
points for previously implicated loci. Frequencies and ORs are from Malhotra and
Sebat (5), except for NRXN1 (4,8); 16p11.2 distal deletion (1) and Williams–
Beuren syndrome duplication (11). For the 22q11.2 deletion, there have been no
carriers reported among 70 739 controls, leading to a frequency of 0% and
OR¼ infinity. In order to fit more realistic data points into the figure, we added
one carrier in controls and scaled down the OR to 99, as no factor can increase
the risk for a disease with a population frequency of 1% by more than 100-fold.
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functions as a subunit of GABA-A receptors (25). Another prom-
ising candidate is GNB1, a member of the previously implicated
N-methyl-D-aspartic acid (NMDAR) gene pathway (26). It is
also possible that the disruption of all five genes increases risk
for SCZ.
CGNL1 duplication
Our strongest statistical result for CNVs hitting a single gene
involves duplications of cingulin-like 1 (CGNL1), where we
find exons disrupted in 0.32% of cases and 0.19% of controls
(CMH P ¼ 0.0019). The duplications are mostly identical in
size and do not cover the whole gene (Supplementary Material,
Fig. S12). CGNL1 is found at adherent junctions and tight cell–
cell junctions and coordinates junction assembly via Rac1 and
RhoA GTPases (27,28). In the case–control analysis by Levin-
son et al. (4), duplications of this gene were reported as having
suggestive evidence for association with schizophrenia, but
this was only presented in their Supplemental Material. That
study used the Molecular Genetics of Schizophrenia (MGS)
and International Schizophrenia Consortium (ISC) cohorts,
similar to our replication sample.
SLC1A1 deletions
SLC1A1 encodes a high-affinity glutamate transporter respon-
sible for inactivating synaptic glutamate and preventing extra-
cellular levels of glutamate from reaching neurotoxic levels
(29). Glutamate acts on NMDAR receptors, and a large body
of evidence has associated NMDAR dysfunction with schizo-
phrenia (30). We find non-recurrent exonic deletions in
0.047% of cases and 0.0075% of controls (CMH P ¼ 0.0098).
Recently, Myles-Worsley et al. (31) reported a deletion of this
gene to co-segregate with schizophrenia and bipolar schizo-
affective disorder in a five-generation family, reaching a lod-
score of 3.64. To our knowledge, this is the first time a CNV
linkage association has received support from a large case–
control analysis in schizophrenia. Additional observations of
SLC1A1 deletions in disease cohorts include one exonic deletion
in 235 subjects with both SCZ and epilepsy (32), a single exonic
deletion in 459 unrelated adults with schizophrenia (33), one
exonic deletion among 1637 German patients with schizophre-
nia or schizoaffective disorder (34) and Cooper et al. (17)
report an enrichment of SLC1A1 deletions in neurological, cra-
niofacial and epilepsy cases.
In conclusion, we have used a large sample of patients and
controls to discover new CNV susceptibility loci. This sample
has the power to detect on its own a large proportion of the pre-
viously associated CNV loci (Fig. 2 and Supplementary Mater-
ial, Table S3). We suggest a role for an additional 12 new loci, but
only one of these was significant in our replication sample, and
even that result does not withstand correction for multiple
testing. Therefore, these results need independent confirmation
in further large samples. Excluding loci that are already strongly
implicated, an excess burden of large and rare CNVs remains in
cases, indicating that there are likely to be further susceptibility
genes disrupted by CNVs, but these will be of smaller effect
size, or very rare, so would require even larger samples to be
identified.
MATERIALS AND METHODS
‘The discovery sample’ consisted of 7129 schizophrenic cases
(prior to quality control (QC) filtering) from the CLOZUK
(N ¼ 6558) and the CardiffCOGS (N ¼ 571) samples, which
have been previously described (6,15,35) but have not yet con-
tributed to any analysis aimed at identifying new CNV loci.
Briefly, the CLOZUK sample consists of patients taking the anti-
psychotic clozapine, a drug reserved in the UK for patients that
have not responded to trials of at least two other antipsychotics.
To allow for early detection of neutropaenia that can result from
treatment with clozapine, patients are required to provide regular
blood samples. Through collaboration with Novartis, the manu-
facturer of a proprietary form of clozapine (Clozaril), we
acquired anonymized DNA samples from people with schizo-
phrenia who were taking the drug. Approval by the local ethics
committee was granted for the use of these samples in genetic as-
sociation studies. Patients are aged 18–90, had a recorded diag-
nosis of treatment resistant schizophrenia, and 71% are male. A
higher male ratio is not unusual for samples recruited for genetic
studies in schizophrenia: this proportion is 66% in the ISC study
(2) and 70% in the MGS study (4). The CardiffCOGS is a sample
of clinically diagnosed schizophrenia patients from the UK.
Interview with the SCAN instrument (36) and case note review
was used to arrive at a best-estimate lifetime diagnosis according
to DSM-IV criteria (37). All discovery cases were genotyped at
the Broad Institute, Stanley Centre for Psychiatric Research,
USA on either Illumina OmniExpress or OmniCombo arrays.
The discovery control cohort consisted of four publicly avail-
able, non-psychiatric datasets, totaling 12 080 samples prior to
QC (Supplementary Material, Table S2). These datasets were
chosen as they were genotyped on Illumina arrays similar to
those used for the cases: Illumina Human Omni2.5, Illumina
HumanOmni1_Quad or Illumina 1.2M. Further details of these
samples are provided in the Supplementary Material.
CNV calling and QC
Principal component analysis was performed to derive ethnicities
of discovery samples. Identity by decent was performed to iden-
tify and remove duplicate individuals. For each case and control
dataset, Log R Ratios (LRR) and B-allele frequencies were gener-
ated using Illumina Genome Studio software (v2011.1) and used
to call CNVs with PennCNV (38). CNV calling was performed
following the standard protocol and adjusting for GC content.
To avoid a cross-platform CNV locus detection bias in the discov-
ery sample, we called CNVs using a consensus set of 520 766
probes that are present on all microarrays used. Samples were
excluded if they were found to be an outlier for any one of the fol-
lowing QC metrics: LRR standard deviation, B-allele frequency
drift, wave factor and total number of CNVs called per person.
The numbers of discovery cases and controls that passed QC are
presented in Table 2. All coordinates in this paper are according
to UCSC build 37, hg19.
CNVs from samples that passed QC were joined together if
the distance separating them was ,50% of their combined
length using an in-house developed open source program
(http://x004.psycm.uwcm.ac.uk/~dobril/combine_CNVs/). CNVs
were then excluded if they were either ,10 kb, covered by
,10 probes, overlapped with LCRs by .50% of their length
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or had a probe density of ,1 SNP/20 kb. CNV loci with a fre-
quency .1% in all samples were excluded using PLINK (39).
Finally, all CNVs were validated by the in silico median
Z-score outlier method, described in detail elsewhere (26) and
in the Supplementary Material. Briefly, this method uses the
median value of all normalized LRR probe intensities within a
CNV to assess copy number. All CNVs in regions enriched
among cases in our Discovery sample that passed our filtering
criteria are available in Supplementary Material, Table S6.
‘Replication samples’ consisted of six independent case/
control datasets and one trio dataset, totaling of 14 568 cases
and 15 274 controls after QC: MGS (4), split for samples with
a European American or African American ancestry; Inter-
national Schizophrenia Consortium (2); Bulgarian trios (BG
trios) (26); Irish (40); Swedish (41); and African American
from the Genomic Psychiatry Cohort in the United States (42).
Bulgarian probands from the BG trios sample were excluded
from the ISC sample, and the Swedish sample does not include
individuals who were part of the ISC. The number of replication
samples that passed QC and the arrays they were genotyped on
are presented in Table 2. Further details on genotyping and QC
of these datasets are presented in the Supplementary Material.
Statistical analysis
To identify novel risk loci we adopted a gene-based approach.
Each gene in the genome was examined for exon-disrupting
CNVs using refseq gene coordinates (downloaded from the
UCSC genome browser, includes non-coding RNAs). Deletions
and duplications were counted and analyzed separately. Genes
that reached nominal levels of significance in the discovery
sample with a two-sided Fisher’s exact test (P, 0.05) were
further analyzed with a one-sided Fisher’s exact test in the repli-
cation data. The combined sample of all available data was
analyzed with a CMH test, stratified by dataset: discovery
sample as a single dataset and each of the seven replication data-
sets as separate samples, as shown in Table 2 (the MGS sample
was split for ethnicity). This gene-wise approach can capture
signal from both single gene enrichments, such as NRXN1 dele-
tions, and larger recurrent events through contiguous gene
enrichments.
The burden of large and rare CNVs in cases versus controls
was evaluated with a one-sided test and 10 000 permutations
using PLINK (39). The analysis was stratified by CNV size
(.500, 500–1 and.1 Mb) and CNV type (all CNVs, deletions
only and duplications only). All CNVs .500 kb used in the
burden analysis are listed in Supplementary Material, Table S7.
Inorder todetermine theeffect size andpopulationfrequencyof
CNVs that our discovery sample had 80% power to detect with an
a of 0.05 (Fig. 2), we used an online open source genetic power
calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/) (43).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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